For instance, a clear role has been established for the histone methyltransferases (HMTs) multiple myeloma SET domain (MMSET) and enhancer of zeste 2 (EZH2) in the DR against the alkylating agent melphalan and PIs/IMiDs respectively [7, 8]. Here, EZH2 is linked to plasma cell myeloma.